Ketamine for the treatment of addiction: Evidence and potential mechanisms
This review (2018) looks at the studies done with ketamine for the treatment of addiction. The results are promising and various mechanisms underlie these effects. Both effects at the neurological (neurogenesis, neuroplasticity, and more) and psychological (mystical experience, reconsolidation of drug-related memories) are discussed.
Abstract
Ketamine is a dissociative anaesthetic drug which acts on the central nervous system chiefly through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Recently, ketamine has attracted attention as a rapid-acting anti-depressant but other studies have also reported its efficacy in reducing problematic alcohol and drug use. This review explores the preclinical and clinical research into ketamine's ability to treat addiction. Despite methodological limitations and the relative infancy of the field, results thus far are promising. Ketamine has been shown to effectively prolong abstinence from alcohol and heroin in detoxified alcoholics and heroin dependent individuals, respectively. Moreover, ketamine reduced craving for and self-administration of cocaine in non-treatment seeking cocaine users. However, further randomised controlled trials are urgently needed to confirm ketamine's efficacy. Possible mechanisms by which ketamine may work within addiction include: enhancement of neuroplasticity and neurogenesis, disruption of relevant functional neural networks, treating depressive symptoms, blocking reconsolidation of drug-related memories, provoking mystical experiences and enhancing psychological therapy efficacy. Identifying the mechanisms by which ketamine exerts its therapeutic effects in addiction, from the many possible candidates, is crucial for advancing this treatment and may have broader implications understanding other psychedelic therapies. In conclusion, ketamine shows great promise as a treatment for various addictions, but well-controlled research is urgently needed.
Research Summary of 'Ketamine for the treatment of addiction: Evidence and potential mechanisms'
Introduction
Addiction is framed as a chronic, relapsing disorder defined by craving, habitual drug-seeking and an aversive abstinence state, and it remains a major public-health and economic burden worldwide. Existing pharmacotherapies are limited: some serve as substitutes (for example methadone) while others modestly support abstinence, but several dependencies (notably stimulants and cannabis) lack convincing drug treatments and relapse rates for current therapies remain high (40%–80% at one year). Against this background, novel approaches are urgently required. Ezquerra-Romano and colleagues set out to review preclinical and clinical evidence for ketamine as a treatment for addiction and to examine plausible mechanisms by which it might reduce drug use and relapse. The review considers historical and pharmacological context, animal studies, clinical trials and uncontrolled clinical programmes, and discusses candidate mechanisms including neuroplasticity, network-level effects, antidepressant action, memory reconsolidation, the subjective psychedelic/mystical experience, and facilitation of psychotherapy.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Authors
- APA Citation
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. (2018). Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology, 142, 72-82. https://doi.org/10.1016/j.neuropharm.2018.01.017
References (22)
Papers cited by this study that are also in Blossom
Ionescu, D. F., Vande Voort, J. L., Niciu, M. J. et al. · Journal of Psychiatric Research (2014)
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Dakwar, E., Anerella, C., Hart, C. L. et al. · Drug and Alcohol Dependence (2014)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Krupitsky, E. M., Burakov, A. M., Romanova, T. N. et al. · Journal of Substance Abuse Treatment (2002)
Show all 22 referencesShow fewer
Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V. et al. · Journal of Psychoactive Drugs (2007)
Krupitsky, E. M., Grinenko, A. Y. · Journal of Psychoactive Drugs (1997)
Morgan, C. J. A., McAndrew, A., Stevens, T. et al. · Current Opinion in Behavioral Sciences (2017)
Paul, R. K., Singh, N. S., Khadeer, M. et al. · Anesthesiology (2014)
Singh, J. B., Fedgchin, M., Daly, E. J. et al. · American Journal of Psychiatry (2016)
Sos, P., Klirova, M., Novák, T. et al. · Neuropsychiatric Disease And Treatment (2013)
Strassman, R. J. · Journal of Nervous and Mental Disease (1995)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Yang, C., Shirayama, Y., Zhang, J-C. et al. · Translational Psychiatry (2020)
Zanos, P., Moaddel, P. J., Morris, P. J. et al. · Nature (2016)
Zhang, J., Hashimoto, K., Li, S. · Pharmacology Biochemistry and Behavior (2014)
Cited By (9)
Papers in Blossom that reference this study
Gent, E. M., Bryan, J. W., Cleary, M. A. et al. · Journal of Psychopharmacology (2024)
Zafar, R., Siegel, M., Harding, R. et al. · Frontiers in Psychiatry (2023)
Gao, Z., Winhusen, |. T. J., Gorenflo, |. M. et al. · Addiction (2023)
Grabski, M., McAndrew, A., Lawn, W. et al. · American Journal of Psychiatry (2022)
Keeler, J. L., Treasure, J., Juruena, M. F. et al. · Nutrients (2021)
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J. et al. · Frontiers in Psychiatry (2021)
Rothberg, R. L., Azhari, N., Haug, N. A. et al. · Journal of Psychopharmacology (2020)
Ona, G., Troncoso, S. · Journal of Psychedelic Studies (2019)
Abdallah, C. G., Sanacora, G., Duman, R. S. et al. · Chronic Stress (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.